The U.S. Food and Drug Administration (FDA) has recently approved the chimeric antigen receptor T-cell (CAR-T) therapy, a new therapy for a type of lymphoma, developed by Gilead Science’s acquired unit Kite Pharma. This marks the second approval for the potentially groundbreaking approach to fighting cancer after the FDA approved Novartis’ Kymriah back in August.